We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ENVX:NASDAQEnovix Corporation Analysis

Data as of 2026-06-13 - not real-time

$6.66

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Enovix (ENVX) is trading at $6.66, below its 20‑day SMA of 7.10 and its 200‑day SMA of 7.86, while hovering just under the 50‑day SMA of 6.70. The RSI of 45.9 signals a neutral momentum environment, yet the MACD is in a bearish configuration (negative histogram) and volume has been trending down, suggesting short‑term pressure. On the fundamentals side, the company posted a 49% revenue surge to $34.3 M, but margins remain weak (operating margin –5.8%) and cash flow is negative, with $528 M of cash offset by $544 M of debt, yielding a debt‑to‑equity of over 200%. Analysts are optimistic, rating the stock a “buy” with a mean target of $13.1, implying a potential upside of nearly 100%, but the current valuation metrics—price‑to‑sales of 42× and price‑to‑book of 5.9×—appear stretched given the earnings deficits. High volatility (101% 30‑day) and a beta above 3 underscore a stock that will swing sharply with market sentiment, especially as the battery sector faces regulatory scrutiny and scaling challenges.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price below short‑term moving averages
  • Bearish MACD and decreasing volume
  • Neutral RSI indicating no clear momentum

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • 49% YoY revenue growth and expanding addressable market
  • Strategic hire of senior sales VP to accelerate commercial scale‑up
  • Analyst consensus target price near $13 suggesting upside

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Secular demand from AI‑enabled devices, EVs, and defense applications
  • Large cash reserves to fund R&D and debt reduction
  • Potential to capture market share with differentiated silicon‑anode technology

Key Metrics & Analysis

Financial Health

Revenue Growth49.10%
P/E Ratio-11.6
ROE-71.31%
ROA-16.68%
Debt/Equity224.03
P/B Ratio5.9
Op. Cash Flow$-111456000
Free Cash Flow$-72119248
Industry P/E30.6

Technical Analysis

TrendNeutral
RSI45.9
Support$5.39
Resistance$9.15
MA 20$7.10
MA 50$6.70
MA 200$7.86
MACDBearish
VolumeDecreasing
Fear & Greed Index89.86

Valuation

Target Price$13.10
Upside/Downside96.70%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta3.54
Volatility101.10%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.